---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-013150"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:17:32.177350+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics appoints Sekar Kathiresan, M.D. to Board of Directors

## Summary
- Dr. Kathiresan appointed as class III director effective July 25, 2022, filling a newly created vacancy expanding board to eight members.
- He is co-founder and CEO of Verve Therapeutics (VVTA) and serves on its board; previously director at MGH Center for Genomic Medicine and Broad Institute.
- He will receive an initial option grant for 71,881 shares vesting over 36 months, plus standard non-employee director compensation.
- Also appointed to the Nominating and Corporate Governance Committee.

## SEC filing metadata
- accession: 0000950170-22-013150
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022013150/0000950170-22-013150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022013150/rlay-20220725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-013150
- JSON: https://secwatch.observer/filing/0000950170-22-013150.json
- Plain text: https://secwatch.observer/filing/0000950170-22-013150.txt

## Key facts
- Executive change
  Sekar Kathiresan was appointed as Director at Relay Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On July 25, 2022, the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Sekar Kathiresan, M.D. to the Board as a class III director to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017022013150/0000950170-22-013150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.